Business / Finance

RSS

Sirona first quarter revenue increases 9.7% to $235.6 million

Sirona, the dental technology leader, today announced its financial results for the quarter ended December 31, 2010.

4 Feb 2011

Cord Blood America signs second Supply Agreement with premier cell and tissue bank

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has signed a Supply Agreement with a premier national and international cell and tissue bank to provide placenta, umbilical cord blood and whole umbilical cord collection services for research purposes.

4 Feb 2011

Prognosis brings EHR success to providers across the country

Prognosis Health Information Systems is making good on its mission of bringing electronic health records success to providers across the country.

4 Feb 2011

CAB expands offerings to EMS Transport business

CAB Receivables Management, a leader in creating cash flow performance solutions for specific industries, has expanded its offerings to the EMS Transport business.

4 Feb 2011

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

AMRI announced today that it has received approval from the Italian Medicines Agency (AIFA) for its facility in Burlington, MA to manufacture the commercial drug product octreotide for a customer in the European Union (EU).

4 Feb 2011

Pacira prices initial public offering at $7.00 per share

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions.

4 Feb 2011

Grubb & Ellis Healthcare announces acquisition of Columbia Long-Term Acute Care Hospital

Grubb & Ellis Healthcare REIT II, Inc. today announced that it has acquired Columbia Long-Term Acute Care Hospital, a single-story, 31,000-square-foot, Class A single-tenant medical facility in Columbia, midway between Kansas City and St. Louis. The acquisition closed on Jan. 31.

3 Feb 2011

ZIOPHARM prices underwritten public offering of 9,600,000 shares of common stock

ZIOPHARM Oncology, today announced the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.75 per share.

3 Feb 2011

NCR fourth-quarter revenue increases 5% to $1.4 billion

NCR Corporation reported financial results today for the three months ended December 31, 2010. Reported revenue of $1.4 billion increased 5 percent from the fourth quarter of 2009 on both an actual and constant currency basis.

3 Feb 2011

Repros prices public offering of 2,760,000 shares of common stock

Repros Therapeutics today announced the pricing of its public offering of 690,000 units, consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15.

3 Feb 2011

Nitto Denko announces acquisition of Avecia Biotechnology

Japan's leading diversified materials manufacturer, Nitto Denko Corporation, today announced that it has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey.

3 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

NeuroMetrix fourth quarter total revenues decrease to $3.1 million

NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.

3 Feb 2011

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2010 and provided guidance for 2011.

3 Feb 2011

Blue Cross and Blue Shield of Minnesota, American Cancer Society receive CEO Cancer Gold Standard accreditation

Blue Cross and Blue Shield of Minnesota and the American Cancer Society - High Plains Division have received CEO Cancer Gold Standard™ accreditation, recognizing the commitment of these organizations to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

3 Feb 2011

Transcend fourth quarter revenue increases 26% to $26,976,000

TRANSCEND SERVICES, INC., a leading provider of clinical documentation solutions to the U.S. healthcare market, today announced its unaudited financial results for the fourth quarter and year ended December 31, 2010.

3 Feb 2011

CIGNA fourth quarter shareholders' net income increases to $461 million

CIGNA Corporation today reported shareholders' net income of $461 million, or $1.69 per share, for the fourth quarter of 2010 compared with shareholders' net income of $330 million, or $1.19 per share, for the fourth quarter of 2009.

3 Feb 2011

MEDNAX fourth quarter net income increases to $53.8 million

MEDNAX, Inc., the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecialty and anesthesia physician services today reported earnings per share of $1.12 for the three months ended December 31, 2010, that were driven by the Company's successful acquisition efforts throughout the year.

3 Feb 2011

PBOI to leverage revenue cycle management services from NextGen Practice Solutions

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, Inc. and leading provider of healthcare information systems and connectivity solutions, today announced that Palm Beach Orthopaedic Institute will leverage revenue cycle management services from NextGen Practice Solutions to optimize its collections and drive business growth.

3 Feb 2011

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Angiotech Pharmaceuticals, today announced that on February 1, 2011, Angiotech received a letter from the Toronto Stock Exchange stating that Angiotech's common shares will be delisted from the TSX effective at the close of market on March 3, 2011.

3 Feb 2011